Drug Trial Radar · NCT06975865
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Aug 12, 2025
Primary completion
Jul 23, 2027
Study completion Dec 29, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, flexible-adaptive, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B). Double-blind period has two parts, 50% (adult only) until the interim analysis (a proof-concept part analogous to a phase 2b study), and 50% (adult and children) after the interim analysis. Only the participants who complete double-blind treatment period (Part A) are eligible to continue to the LTE period. The duration of the LTE period (Part B) will be from the first-participant-in (FPI)-LTE (Part B) until the last participant who enters the LTE has completed 52 weeks. * Treatment duration: 52-week double-blind period (Part A); LTE period (Part B) from the (FPI until the last participant who enters the LTE has completed 52 weeks. * Visit frequency: Week visits based on the Schedule of Assessments.
Conditions
- Sickle Cell Disease
Interventions
RilzabrutinibDrug
Pharmaceutical form:Tablet -Route of administration:Oral
PlaceboDrug
Pharmaceutical form:Tablet -Route of administration:Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of clinical VOCTime frame: At Week 52
Locations
64 sites in 14 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham- Site Number : 8400003
Birmingham, Alabama · Recruiting
Phoenix Children's Hospital- Site Number : 8400028
Phoenix, Arizona · Recruiting
University of California San Francisco- Site Number : 8400040
Clovis, California · Recruiting
David Geffen School of Medicine at UCLA- Site Number : 8400032
Los Angeles, California · Recruiting
MedStar Georgetown University Hospital- Site Number : 8400036
Washington D.C., District of Columbia · Recruiting
Oncology & Hematology Associates of West Broward- Site Number : 8400029
Coral Springs, Florida · Recruiting
Sylvester Comprehensive Cancer Center- Site Number : 8400020
Miami, Florida · Recruiting
University of Illinois-Chicago - College of Medicine- Site Number : 8400054
Chicago, Illinois · Recruiting
Indiana University Health Riley Hospital for Children- Site Number : 8400056
Indianapolis, Indiana · Recruiting
Louisiana State University Health Sciences Center - Shreveport- Site Number : 8400037
Shreveport, Louisiana · Recruiting
University of Maryland School of Medicine - Baltimore- Site Number : 8400041
Baltimore, Maryland · Recruiting
University of Michigan Health System - Ann Arbor- Site Number : 8400035
Ann Arbor, Michigan · Recruiting
Southern Specialty Research- Site Number : 8400059
Flowood, Mississippi · Recruiting
Richmond University Medical Center- Site Number : 8400038
Staten Island, New York · Recruiting
Montefiore Medical Center - Moses Campus- Site Number : 8400057
The Bronx, New York · Recruiting
Oregon Health & Science University (OHSU)- Site Number : 8400043
Portland, Oregon · Recruiting
Prisma Health- Site Number : 8400051
Greenville, South Carolina · Recruiting
University of Tennessee Health Science Center- Site Number : 8400045
Memphis, Tennessee · Recruiting
Baylor College of Medicine- Site Number : 8400055
Houston, Texas · Recruiting
UT Physicians - Memorial Hermann- Site Number : 8400052
Houston, Texas · Recruiting
VCU Massey Cancer Center: Dalton Oncology Clinic- Site Number : 8400012
Richmond, Virginia · Recruiting
Investigational Site Number : 0560003
Brussels, Belgium · Recruiting
Investigational Site Number : 0560002
Brussels, Belgium · Recruiting
Investigational Site Number : 0560001
Leuven, Belgium · Recruiting
Investigational Site Number : 0560004
Liège, Belgium · Recruiting
Hospital Samaritano De Sao Paulo- Site Number : 0760005
São Paulo, Brazil · Recruiting
Hospital Santa Izabel- Site Number : 0760006
Salvador, Estado de Bahia, Brazil · Recruiting
Fundação Bahiana de Infectologia- Site Number : 0760009
Salvador, Estado de Bahia, Brazil · Recruiting
Universidade Federal de Goias- Site Number : 0760002
Goiânia, Goiás, Brazil · Recruiting
Fundação Faculdade Regional de Medicina de São José do Rio Preto- Site Number : 0760001
São José do Rio Preto, São Paulo, Brazil · Recruiting
Investigational Site Number : 2500002
Créteil, France · Recruiting
Investigational Site Number : 2500005
Marseille, France · Recruiting
Investigational Site Number : 2500001
Paris, France · Recruiting
Investigational Site Number : 2500004
Toulouse, France · Recruiting
Investigational Site Number : 2760005
Berlin, Germany · Recruiting
Investigational Site Number : 2760002
Essen, Germany · Recruiting
Investigational Site Number : 2760004
Stuttgart, Germany · Recruiting
Investigational Site Number : 3000001
Athens, Greece · Recruiting
Investigational Site Number : 3000003
Athens, Greece · Recruiting
Investigational Site Number : 3000002
Pátrai, Greece · Recruiting
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.